Stock Track | Moderna Soars Over 5% Intraday on First mRNA Flu Vaccine FDA Approval and Q2 Earnings Beat

Stock Track00:00

Moderna, Inc. shares surged 5.18% during intraday trading on Wednesday, propelled by a pair of positive developments: regulatory approval for its groundbreaking mRNA flu vaccine and stronger-than-expected second-quarter financial results.

The U.S. Food and Drug Administration granted approval to mFLUSIVA, Moderna's seasonal influenza vaccine for adults aged 50 and older. This milestone marks the company's fourth approved product in the U.S. and represents the first-ever mRNA vaccine to enter the competitive flu market. Moderna expects the vaccine to be available at select retail channels in the coming weeks for the 2026-2027 respiratory virus season, with additional regulatory reviews ongoing in Australia, Canada, and Europe.

On the earnings front, Moderna reported a second-quarter loss per share of $1.97, which was narrower than the FactSet consensus estimate of a $2.01 loss. Revenue of $145 million significantly exceeded the $102.9 million analyst forecast, and the company reiterated its target of 10% year-over-year revenue growth. In response to the upbeat results, multiple investment banks raised their price targets, with Goldman Sachs adjusting to $67 and Jefferies to $60, both maintaining Hold ratings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143203479?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143203479","market":"us","top_or_hot":-1,"title":"Stock Track | Moderna Soars Over 5% Intraday on First mRNA Flu Vaccine FDA Approval and Q2 Earnings Beat","media":"Stock Track","content":"<p>Moderna, Inc. shares surged 5.18% during intraday trading on Wednesday, propelled by a pair of positive developments: regulatory approval for its groundbreaking mRNA flu vaccine and stronger-than-expected second-quarter financial results.</p><p>The U.S. Food and Drug Administration granted approval to mFLUSIVA, Moderna's seasonal influenza vaccine for adults aged 50 and older. This milestone marks the company's fourth approved product in the U.S. and represents the first-ever mRNA vaccine to enter the competitive flu market. Moderna expects the vaccine to be available at select retail channels in the coming weeks for the 2026-2027 respiratory virus season, with additional regulatory reviews ongoing in Australia, Canada, and Europe.</p><p>On the earnings front, Moderna reported a second-quarter loss per share of $1.97, which was narrower than the FactSet consensus estimate of a $2.01 loss. Revenue of $145 million significantly exceeded the $102.9 million analyst forecast, and the company reiterated its target of 10% year-over-year revenue growth. In response to the upbeat results, multiple investment banks raised their price targets, with Goldman Sachs adjusting to $67 and Jefferies to $60, both maintaining Hold ratings.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars Over 5% Intraday on First mRNA Flu Vaccine FDA Approval and Q2 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars Over 5% Intraday on First mRNA Flu Vaccine FDA Approval and Q2 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-13 00:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. shares surged 5.18% during intraday trading on Wednesday, propelled by a pair of positive developments: regulatory approval for its groundbreaking mRNA flu vaccine and stronger-than-expected second-quarter financial results.</p><p>The U.S. Food and Drug Administration granted approval to mFLUSIVA, Moderna's seasonal influenza vaccine for adults aged 50 and older. This milestone marks the company's fourth approved product in the U.S. and represents the first-ever mRNA vaccine to enter the competitive flu market. Moderna expects the vaccine to be available at select retail channels in the coming weeks for the 2026-2027 respiratory virus season, with additional regulatory reviews ongoing in Australia, Canada, and Europe.</p><p>On the earnings front, Moderna reported a second-quarter loss per share of $1.97, which was narrower than the FactSet consensus estimate of a $2.01 loss. Revenue of $145 million significantly exceeded the $102.9 million analyst forecast, and the company reiterated its target of 10% year-over-year revenue growth. In response to the upbeat results, multiple investment banks raised their price targets, with Goldman Sachs adjusting to $67 and Jefferies to $60, both maintaining Hold ratings.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1143203479","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143203479","pubTimestamp":1786550446,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. shares surged 5.18% during intraday trading on Wednesday, propelled by a pair of positive developments: regulatory approval for its groundbreaking mRNA flu vaccine and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"股票跟踪 | Moderna 首个 mRNA 流感疫苗获得 FDA 批准，第二季度盈利超出预期，盘中飙升超过 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. shares surged 5.18% during intraday trading on Wednesday, propelled by a pair of positive developments: regulatory approval for its groundbreaking mRNA flu vaccine and stronger-than-expected second-quarter financial results.The U.S. Food and Drug Administration granted approval to mFLUSIVA, Moderna's seasonal influenza vaccine for adults aged 50 and older. This milestone marks the company's fourth approved product in the U.S. and represents the first-ever mRNA vaccine to enter the competitive flu market. Moderna expects the vaccine to be available at select retail channels in the coming weeks for the 2026-2027 respiratory virus season, with additional regulatory reviews ongoing in Australia, Canada, and Europe.On the earnings front, Moderna reported a second-quarter loss per share of $1.97, which was narrower than the FactSet consensus estimate of a $2.01 loss. Revenue of $145 million significantly exceeded the $102.9 million analyst forecast, and the company reiterated its target of 10% year-over-year revenue growth. In response to the upbeat results, multiple investment banks raised their price targets, with Goldman Sachs adjusting to $67 and Jefferies to $60, both maintaining Hold ratings.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143203479","isCrawlerRequest":true}